The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open- label study

Herrera-Estrella, Miguel; Apiquian, Rogelio; Fresan, Ana; Sanchez-Torres, Isabel
January 2005
BMC Psychiatry;2005, Vol. 5, p22
Academic Journal
Background: The efficacy of antipsychotics can be evaluated using the dimensional models of schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and tolerability to other atypical antipsychotics. The aim of the present study was to determine the efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin schizophrenic patients. Method: Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label 3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and side-effects were evaluated with standardized scales. Results: The patients showed significant improvement in the five dimensions evaluated. Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent extrapyramidal side-effects. Conclusion: Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia.


Related Articles

  • First rank symptoms as predictors of ECT response in schizophrenia. Koehler, Karl; Sauer, Heinrich; Koehler, K; Sauer, H // British Journal of Psychiatry;Mar83, Vol. 142, p280 

    First rank symptoms (FRS) in association with affective features predict improvement on ECT. When affectivity was disregarded in 142 schizophrenic probands given ECT and the relationship between FRS alone and ECT response examined, those without FRS had a significantly better ECT outcome score...

  • The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Four rare cases in Ireland. Waddington, John L.; Youssef, Hanafy A.; Waddington, J L; Youssef, H A // British Journal of Psychiatry;Jan90, Vol. 156, p106 

    Four elderly schizophrenic patients who had never been treated with neuroleptics, and a fifth patient who had received only the briefest exposure to such drugs, had retained their distinct clinical characteristics. Involuntary orofacial movements and cognitive dysfunction were found more...

  • Canadian Clinical Practice Guidelines for the Treatment of Schizophrenia.  // Canadian Journal of Psychiatry;Nov1998 Supplement, Vol. 43, p25s 

    The article discusses the guidelines issued by the Canadian Clinical Practice to improve the assessment and treatment of patients with schizophrenia. These are said to be written by a working group that include psychiatrists and psychologists, expert in the assessment and treatment of the...

  • ECHOPRAXIA IN SCHIZOPHRENIA. Chapman, James; McGhie, Andrew; CHAPMAN, J; MCGHIE, A // British Journal of Psychiatry;May64, Vol. 110 Issue 466, p365 

    The article provides an overview concerning the echopraxia in schizophrenia in Great Britain. The term echopraxia refers to the automatic repetition by an individual of visually perceived actions of others. It was reported to occur in the variety of pathological mental states. There were some...

  • lack of tolerable treatment options for patients with schizophrenia. Citrome, Leslie; Eramo, Anna; Francois, Clement; Duffy, Ruth; Legacy, Susan N.; Offord, Steve J.; Krasa, Holly B.; Johnston, Stephen S.; Guiraud-Diawara, Alice; Kamat, Siddhesh A.; Rohman, Patricia // Neuropsychiatric Disease & Treatment;Dec2015, Vol. 11, p3095 

    Purpose: Atypical antipsychotics (AAs), an effective treatment for schizophrenia, have a range of pharmacologic properties leading to differences in tolerability as well as heterogeneity in treatment response. Individual patient characteristics must be considered when making treatment choices,...

  • EVALUATION OF NEUROTHERAPY PROGRAM FOR A PATIENT WITH CLINICAL SYMPTOMS OF SCHIZOPHRENIA AND SEVERE TBI USING EVENT-RELATED POTENTIALS. Pachalska, Maria; Pronina, Marina V.; Manńo, Grzegorz; Chantsoulis, Marzena; Mirski, Andrzej; Kaczmarek, Bożydar; Łuckos, Maria; Kropotov, Juri D. // Acta Neuropsychologica;Oct-Dec2013, Vol. 11 Issue 4, p435 

    Background: Despite recent interest in the brain/mind problem and the possible organic correlates of mental disease, relatively few case studies have examined the problem concretely. This article examines the effectiveness of neurotherapy for a 68-year-old male schizophrenic patient whose...

  • A mechanism to inhibit input activation and its dysfunction in schizophrenia. Johnson, J. David; Johnson, J D // British Journal of Psychiatry;Apr85, Vol. 146, p429 

    Schizophrenics appear to be unable to regulate adequately the effects of external stimulation, but the cause of this deficit is unclear. Recent evidence suggests that input activation can normally be inhibited by an appropriate leading or conditioning stimulus; such inhibition has been found to...

  • Efectos de la olanzapina sobre la entrada sensorial auditiva en la esquizofrenia. Arango, Celso; Summerfelt, Ann; Buchanan, Robert W. // American Journal of Psychiatry - Edición Española;Feb2004, Vol. 7 Issue 2, p124 

    No abstract available.

  • Effect of Introducing a Care Pathway to Standardize Treatment and Nursing of Schizophrenia. Marchisio, Sara; Vanetti, Michele; Valsesia, Roberta; Carnevale, Lidia; Panella, Massimiliano // Community Mental Health Journal;Aug2009, Vol. 45 Issue 4, p255 

    Care pathways can help to implement evidence-based clinical practice. The introduction of care pathways is difficult for psychiatric disorders. This study examined whether the organization and the effectiveness of care provided to schizophrenic patients can be improved by care pathways. Outcomes...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics